Amgen Principal Scientist - Modeling and Simulation in Thousand Oaks, California
The Clinical Pharmacology, Modeling & Simulation Department at Amgen is seeking a Principal Scientist, Modeling and Simulation.
The Principal Scientist will be responsible for the development and implementation of the modeling and simulation strategies and activities for Amgen clinical development candidates across multiple novel modalities including T-cell engagers, cellular and nucleic acid based therapies in addition to small molecule and monoclonal antibodies.
In our mission to serve patients, speed is absolutely critical. We’re rapidly expanding our hiring initiatives and are excited to unite with the most passionate and brilliant scientific minds who want to join our team – working toward our mission of advancing high potential programs for cancer patients around the world.
Conducting PK/PD and exposure-response analyses of data from early to late phase clinical studies using pharmacostatistical and relevant state of the art modeling and simulation techniques
Performing meta-analysis using proprietary and/or literature data
Participating in cross-functional project teams and providing scientific input for dose selection for early and late stage clinical study designs using quantitative methods
Contributing to clinical pharmacology plans by establishing and implementing high impact modeling and simulation strategy for clinical development candidates
Authoring PK/PD reports and contributing to summary documents for regulatory submissions
Doctorate degree and 3 years of modeling & simulation scientist experience
Master’s degree and 6 years of modeling & simulation scientist experience
Bachelor’s degree and 8 years of modeling & simulation scientist experience
PhD with 8+ years of experience as modeling & simulation scientist in applied (bio)statistics, (bio)engineering, applied biomathematics/biophysics or related fields with equivalent professional degrees
8+ years of experience as modeling & simulation scientist in the biotechnology/ pharmaceutical industry
Experience in analyzing pharmacokinetic, efficacy and safety data from clinical trials using advanced pharmacometric or statistical modeling methodologies and in conducting clinical trial simulations to assist study design
Experience in binary and categorical data analyses, time-to-event (hazard) models, Poisson models, logistic regression, MCMC and Bayesian methods as applied to exposure-response analyses and Population PK and PKPD analysis
Experience in designing strategic integrated modeling simulation plans in support of development of small molecule and/or protein therapeutics
Experience in regulatory filings (NDA/BLA) and responding to regulatory agency questions and knowledge of global regulatory requirements and guidance on quantitative analyses
Expertise in modeling software (e.g. NONMEM, R, SAS, STAN, MATLAB)
Excellent interpersonal, verbal and written communication skills and the ability to function in a highly matrixed team environment
Previous record of scientific contributions through peer-reviewed articles and external presentations
Our culture is what makes Amgen a special place to work. We have a powerful shared purpose around our mission – to serve patients. We respect one another, recognize contributions, and have embedded collaboration, trust, empowerment and inclusion in all that we do.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.